Streetwise Articles



Jason McCarthy

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease
Source: Streetwise Reports  (5/2/18)
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. More >


Jason McCarthy

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors
Source: Streetwise Reports  (4/25/18)
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront. More >


Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates'
Source: Streetwise Reports   (4/24/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate. More >


John McCamant

Biotech Round-Up: M&As, Financings and Immuno-Oncology
Source: John McCamant for Streetwise Reports  (4/18/18)
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline. More >


Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal
Source: Streetwise Reports  (4/17/18)
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry. More >


Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts
Source: Streetwise Reports  (4/17/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data.


More >


Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick
Source: Streetwise Reports  (4/11/18)
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status.
More >


Biotech Announces Positive Topline Data in Tourette Syndrome
Source: Streetwise Reports  (4/11/18)
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts. More >


RNAi Therapeutics Developer Reports Positive Amyloidosis Data
Source: Streetwise Reports  (4/4/18)
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March. More >


CMS Unexpectedly Issues Product Billing Code to Biotech
Source: Streetwise Reports  (4/4/18)
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm.
More >


John McCamant

Biotech Delivers 'Excellent' Phase 2 Data
Source: John McCamant for Streetwise Reports  (4/3/18)
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial. More >


Medical Device Firm Posts 'Strong Performance' Globally in Q4/17
Source: Streetwise Reports   (3/28/18)
The company performed strongly in the U.S. and the Asia Pacific region. More >


Regrouped Biotech's Stock Price Could See Fifteenfold Increase
Source: Streetwise Reports  (3/28/18)
A recent conference call provided clinical and financial updates. More >


Andrea Bartzen

Convergence Will Drive the Ultimate Disruption of Life Sciences
Source: Andrea Bartzen for Streetwise Reports  (3/28/18)
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night.
More >


Biotech Advances Treatments for Liver Disease, Pain, Mental Illness
Source: Streetwise Reports  (3/22/18)
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018.
More >


Two Biotechs Earn Analyst's Top Pick Ranking
Source: Streetwise Reports  (3/19/18)
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
More >


Price Target on Biotech Is a 700% Potential Increase
Source: Streetwise Reports  (3/19/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. More >


Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3
Source: Streetwise Reports  (3/14/18)
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset. More >


Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'
Source: Streetwise Reports  (3/14/18)
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm. More >


Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside
Source: Streetwise Reports  (3/7/18)
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment. More >


Biotech Launches Trial Dosing Against Backdrop of Strong Balance Sheet
Source: Streetwise Reports  (3/7/18)
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs. More >


Exciting Biotech Stock Now Breaking Out of Large Base
Source: Clive Maund for Streetwise Reports  (3/5/18)
Technical analyst Clive Maund takes a look at a biotech stock that he views as a strong buy. More >


Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'
Source: Streetwise Reports  (2/23/18)
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential.
More >


Steve Palmer

Fund Manager Names Three Small-Caps with Strong Growth Profiles
Source: Streetwise Reports  (2/22/18)
The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects.
More >


Can a Simple Test Really Predict Whether a Cancer Treatment Will Succeed?
Source: Streetwise Reports  (2/20/18)
Imagine if a simple test of a blood or tissue sample could predict whether the standard treatment of care for a cancer would be effective. That day appears to be near for patients with Hodgkin's lymphoma. More >


Showing Results: 26 to 50 of 902 Prev Next

Notable Quotes

"We are initiating coverage on PMN."
– John Vandermosten, Zacks Small-Cap Research

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts